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Abstract Macrosomia risk remains high in type 1 diabetes
(T1DM) complicated pregnancies. A linear relationship
between macrosomia risk and glycated hemoglobin A1c
(HbA1c) was described; however, low range of HbA1c has
not been studied. We aimed to identify risk factors and
examine the impact of HbA1c on the occurrence of mac-
rosomia in newborns of T1DM women from a cohort with
good glycemic control. In this observational retrospective
one-center study we analyzed records of 510 consecutive
T1DM pregnancies (1998–2012). The analyzed group
consisted of 375 term singleton pregnancies. We used
multiple regression models to examine the impact of HbA1c
and self-monitored glucose in each trimester on the risk of
macrosomia and birth weight. The median age of T1DM
women was 28 years, median T1DM duration—11 years,
median pregestational BMI—23.3 kg/m2. Median birth
weight reached 3520 g (1st and 3rd quartiles 3150 and
3960, respectively) at median 39 weeks of gestation. There
were 85 (22.7 %) macrosomic (>4000 g) newborns. Median
HbA1c levels in the 1st, 2nd, and 3rd trimester were 6.4, 5.7,
and 5.6 %. Third trimester HbA1c, mean fasting self-
monitored glucose and maternal age were independent
predictors of birth weight and macrosomia. There was a
linear relationship between 3rd trimester HbA1c and mac-
rosomia risk in HbA1c range from 4.5 to 7.0 %. Macrosomia
in children of T1DM mothers was common despite excel-
lent metabolic control. Glycemia during the 3rd trimester
was predominantly responsible for this condition.
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Introduction
Diabetes is the most common metabolic disease compli-
cating pregnancy [1, 2]. It is associated with increased risk
of maternal and neonatal complications and constitutes a
serious medical, social, and financial problem. There is
ample evidence that regardless of diabetes type, hypergly-
cemia during pregnancy increases risk of adverse outcomes
[3, 4]. Today pregnant women with type 1 diabetes (T1DM)
can achieve a very good glycemic control, however, despite
substantial improvements in diabetes care, the rate of
complications, and particularly macrosomia, remains high
[5–8]. Fetal macrosomia is associated with an increased risk
of cesarean section, injuries to the birth canal and to the
fetus, as well as obesity and metabolic diseases later in life
[9–13].
The HAPO study (Hyperglycemia and Adverse Preg-
nancy Outcomes) revealed that there was no risk threshold
in the association of fetal macrosomia and glycemia mea-
sured during an oral glucose tolerance test performed in
pregnant women without pregestational diabetes [14]. This
observation, together with another clinical trial of glucose
lowering treatment in mild gestational diabetes [15], have
led to conclusion that therapeutic measures to decrease
blood glucose in pregnancy should be addressed to a larger
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population of pregnant women. It subsequently resulted in a
substantial change of diagnostic criteria of gestational dia-
betes worldwide. In pregestational diabetes the target
hemoglobin A1c (HbA1c) during pregnancy is generally
defined at a close to normal level, for example <6.5 % (<47
mmol/mol) according to The National Institute for Health
and Care Excellence [16] or within the range of 6.0–6.5 %
(42–47 mmol/mol) according to the current standards of
diabetes care of The American Diabetes Association [17]. In
the light of the HAPO study results, one can hypothesize
that there is an analogous continuous relationship between
birth weight and HbA1c level in women with T1DM. This
association could be present for HbA1c values below 6%
(42 mmol/mol), prompting reconsideration of current ther-
apeutic targets.
We have earlier reported that women with T1DM
achieved excellent glycemic control in the 2nd and 3rd
trimesters of pregnancy, regardless their insulin treatment
regimen—multiple daily injections or personal insulin
pump [18]. In the current observational study we describe
the relationship between maternal HbA1c, self-monitored
glucose and macrosomia risk in this group, and attempt to
verify the hypothesis that macrosomia remains a glucose-
dependent complication of pregnancy in women with
T1DM, in spite of achievement of therapeutic goals.
Subjects and methods
Subjects
This retrospective, observational, cross-sectional cohort
study was performed at the Department of Metabolic Dis-
eases of the University Hospital, Krakow, Poland, an aca-
demic referral center for diabetes care in South-Eastern
Poland. All pregnant women with pre-existing T1DM were
registered between the years 1998 and 2012 as a continuous
case series. They were all referred to the Department no
later than in the 1st trimester of pregnancy and had a clinical
diagnosis of T1DM established at least one year prior to
conception. The patients were Caucasian residents of South-
Eastern Poland.
The study protocol and its conduct were concordant with
the Helsinki Declaration and it was approved and super-
vised by the Jagiellonian University Bioethical Committee.
All women with diabetes who were pregnant or planned
pregnancy received intensive diabetes management care in
the clinic as described earlier [18]. That management
involved education on diet and physical activity, glycemic
goals and self-monitoring of blood glucose (SMBG), with
self-adjustment of insulin dose. According to the Polish
Diabetes Association recommendations at the time when the
study was performed [19], the therapeutic targets for all
women were: (a) HbA1c < 6.1 % (43 mmol/mol), (b) fast-
ing self-monitored glucose 60–90 mg/dl, and (c) subse-
quent pre- and 1-h postprandial self-monitored within
60–120 mg/dl. Pregnancy planning was defined as descri-
bed earlier [18]. Briefly, the term “pregnancy planning”
refers to the time of entry to our intensive diabetes man-
agement program and applies to women who entered this
program before conception.
Clinical characteristics of the women, information on the
course of pregnancy and glycemic control markers were
collected during regular clinic visits. Diabetic retinopathy
was diagnosed by funduscopy at a visit scheduled during
the 1st trimester and diabetic nephropathy was diagnosed
with urinary albumin and serum creatinine (eGFR)
according to KDIGO guidelines [20]. Pregnancy outcomes
were ascertained during a postpartum visit and from med-
ical records. Birth weight was recorded for all term preg-
nancies. Macrosomia was defined as birth weight >4000 g.
HbA1c was measured with high performance liquid
chromatography (HLPC) on a Variant apparatus (Biorad)
and was DCCT adjusted. The inter- and intra-assay coeffi-
cient of variation was less than 2 %. The clinical laboratory
in which HbA1c was measured participates in an internal
and external quality control program by regularly per-
forming calibration procedures and blind assays of stan-
dardized material.
In each trimester the patient-provided SMBG profile was
recorded during a study visit—it included measurements
from 7 days preceding the visit. The measurements recorded
were typically at least 8 times a day: before and 60 min after
every meal, additionally at bedtime and between 2–4 am.
Corresponding timed non-missing measurements from
consecutive days were averaged. The following variables
were extracted or calculated from SMBG profiles in each
trimester: mean fasting glucose, mean glucose (arithmetic
mean of all measurements), mean postprandial glucose
(arithmetic mean of postprandial measurements) and mean
glucose amplitude (average difference between the highest
and the lowest daily glucose measurement).
Statistical analyses
For descriptive purposes the data is presented as medians
(1st, 3rd quartile) and mean ± standard deviation (SD).
Statistical comparisons between macrosomia and normal
birth weight groups were performed with the Wilcoxon test,
chi-square test of Fisher exact test, where applicable.
To identify independent risk predictors of macrosomia
we used multiple logistic regression analysis. The complete
list of independent variables included: maternal age, T1DM
duration, presence of diabetic retinopathy or nephropathy,
maternal weight and BMI before conception, weight gain
during pregnancy, HbA1c recorded in each of three
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trimesters, mean fasting self-monitored glucose, mean daily
self-monitored glucose, mean postprandial self-monitored
glucose and mean SMBG amplitude, treatment with con-
tinuous subcutaneous insulin infusion (CSII) and pregnancy
planning. We performed a supervised best subset selection
of candidate variables by minimizing Bayesian Information
Criterion. We controlled collinearity with variance inflation
and monitored the confounding properties of predictors. In
the final model we retained all nominally significant pre-
dictors. In addition, the predictors from the final logistic
model were evaluated with multiple linear regression model
for their association with birth weight as a continuous
variable. As a sensitivity analysis we fitted multiple
logistic and linear regression models to data restricted to
women who in all three trimesters had HbA1c< 6.5 % (48
mmol/mol), the current American Diabetes Association
(ADA) and National Institute for Health and Clinical
Excellence (NICE) target; a similar analysis was done for
HbA1c< 6.1 % (43 mmol/mol) during the entire pregnancy.
To dissect how risk of macrosomia depends on different
levels of HbA1c in the 3rd trimester we stratified the dis-
tribution of this marker and calculated risk of macrosomia
in each stratum. First, for graphical assessment we divided
the cohort into six arbitrary groups. An apparent risk
increase above HbA1c of 5.6 % (38 mmol/mol) was tested
with a logistic spline model. Then, to obtain a smooth plot
of the relationship between HbA1c and macrosomia risk we
divided the HbA1c distribution into 15 equal strata, each
containing 25 women. For each stratum we calculated mean
3rd trimester HbA1c and probability of macrosomia. We
used a penalized low-rank thin-plate spline model [21] fitted
to a scatter of 15 macrosomia probabilities by mean 3rd
trimester HbA1c, with knots placed at a regular distance of a
0.3 percentage point between HbA1c 4.5 and 7.5 % (26–59
mmol/mol, 11 knots). The posterior probabilities of model
parameters were estimated through Gibbs sampling (an
example of Markov chain Monte Carlo algorithm). We used
non-informative priors and initial values of fixed-effect
parameters were estimated using restricted maximum like-
lihood. We used 30,000 burn-in iterations, and 100,000
iterations for inference, of which we saved 10,000. Con-
vergence was assessed by visual inspection of trace plots
and density plots from 4 parallel chains, autocorrelation of
time-series and Gelman–Rubin diagnostic.
The analysis was performed with SAS 9.3 software
(Cary, NC, USA), OpenBUGS 3.2.3, R software 3.1.0 (The
R Foundation for Statistical Computing, Vienna, Austria)
using SemiPar and R2OpenBUGS packages. P-values
<0.05 were considered significant.
Results
The exclusion criteria and causes of dropout from the initial
sample size of 510 consecutive patients are presented in
Fig. 1. Briefly, 16 women had incomplete follow-up and/or
missing outcome data, 9 were excluded due to multiple
pregnancy, in 110 women the pregnancy ended before the
37th week. The final analysis included 375 woman–child
pairs. The baseline characteristics of the study population
are presented in Table 1. The median age at first pregnancy
visit was 28 years and T1DM duration was 11 years. The
mothers had generally adequate body weight, with median
BMI 23.3 kg/m2. Consistently with long T1DM duration,
prevalence of retinopathy was 25.6 %. None of the patients
showed evidence of chronic kidney disease of stage 3 or
higher.
Less than one half (41.6 %) of the women entered the
intensive diabetes care program (pregnancy planning). Most
patients during pregnancy were treated with rapid-acting
insulin analogs (60.3 %) and predominantly used insulin
pumps (58.9 %). HbA1c decreased systematically during the
gestational period: from median 6.4 % (46 mmol/mol)
in the first trimester to 5.7 % (39 mmol/mol) and
Fig. 1 Numbers of patients
initially accessed, excluded and
included in the study
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Table 1 Characteristics of the study group
Characteristics Median (1st, 3rd quartile) and mean± standard deviation or count (%) P-value*
No macrosomia N= 291 Macrosomia N= 84 Odds ratio (95 % CI)
Maternal baseline characteristrics
Age (years) 28 (25, 31) 27 (24, 30) 0.76 (0.58, 0.99) 0.026
28± 4.6 27± 5.1 per 5 years ↑
Diabetes duration (years) 11 (5, 18) 10 (5, 16) 0.86 (0.72, 1.02) 0.13
12± 7.6 10± 6.5 per 5 years ↑
BMI before conception (kg/m2) 23.2 (21.7, 25.6) 23.6 (22.0, 25,7) 1.04 (0.97, 1.11) 0.22
23.9± 3.5 24.3± 3.4 per 1 kg/m2 ↑
Retinopathy 82 (28.2 %) 14 (16.6 %) 0.51 (0.27, 0.95) 0.033
Nephropathy 5 (1.7 %) 2 (2.4 %) 1.39 (0.27, 7.32) 0.66
Treatment during pregnancy
Pregnancy planning 122 (41.9 %) 34 (40.5 %) 1.07 (0.65, 1.78) 0.81
Analog insulin 174 (59.8 %) 52 (61.9 %) 1.08 (0.66, 1.79) 0.73
CSII 164 (56.4 %) 57 (67.9 %) 1.63 (0.98, 2.70) 0.059
Glycemic control in 1st trimester
HbA1c (%) (mmol/mol) 6.3 (5.7, 7.2) 6.9 (6.0, 7,5) 1.13 (0.94, 1.35) 0.029
6.6± 1.3 6.8± 1.1 per 1 % ↑
45 (39, 55) 52 (42, 59)
49± 15 51± 12
Mean SMBG glucose (mmol/l) 5.9 (5.4, 6.4) 6.0 (5.5, 6.8) 1.06 (0.88, 1.26) 0.50
6.1± 1.3 6.2± 1.3 per 1 mmol/l ↑
Mean fasting glucose (mmol/l) 5.5 (4.6, 6.5) 6.1 (5.0, 7.2) 1.13 (1.00, 1.28) 0.012
5.8± 1.8 6.3± 2.0 per 1 mmol/l ↑
Glycemic control in the 2nd trimester
HbA1c (%) (mmol/mol) 5.6 (5.1, 6.2) 6.0 (5.4, 6.5) 1.43 (1.12, 1.83) 0.002
5.7± 0.9 6.1± 1.2 per 1 % ↑
38 (32, 44) 42 (36, 48)
39± 10 43± 13
Mean SMBG glucose (mmol/l) 5.6 (5.2, 6.0) 6.0 (5.5, 6.4) 1.45 (1.14, 1.85) <0.001
5.7± 1.0 6.1± 1.0 per 1 mmol/l ↑
Mean fasting glucose (mmol/l) 5.1 (4.5, 5.8) 5.7 (4.9, 6.4) 1.42 (1.18, 1.71) <0.001
5.3± 1.2 5.9± 1.6 per 1 mmol/l ↑
Glycemic control in the 3rd trimester
HbA1c (%) (mmol/mol) 5.5 (5.1, 6.0) 6.0 (5.4, 6.5) 1.81 (1.36, 2.41) <0.001
5.6± 0.8 6.1± 0.9 per 1 % ↑
37 (32, 42) 42 (37, 48)
38± 9 43± 10
Mean SMBG glucose (mmol/l) 5.7 (5.1, 6.2) 5.9 (5.4, 6.5) 1.48 (1.15, 1.92) 0.001
5.7± 0.9 6.1± 0.9 per 1 mmol/l ↑
Mean fasting glucose (mmol/l) 5.0 (4.4, 5.7) 5.4 (4.9, 6.4) 1.52 (1.24, 1.87) <0.001
5.1± 1.1 5.8± 1.5 per 1 mmol/l ↑
Follow-up outcomes
Duration of pregnancy (weeks) 39 (38, 40) 39 (39, 41) 1.22 (1.03, 1.43) 0.029
39± 1.4 40± 1.6 per 1 week ↑
Weight gain during pregnancy (kg) 15 (11, 19) 16 (11, 19) 1.01 (0.97, 1.05) 0.32
15± 6.2 15± 6.5 per 1 kg ↑
Cesarean deliveries 198 (68.0 %) 53 (63.1 %) 0.83 (0.49, 1.41) 0.40
Birth weight (g) 3370 (3060, 3650) 4290 (4155, 4565) – <0.001
3336± 397 4371± 306
*Comparison of medians or frequencies in macrosomia vs. no macrosomia
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5.6 % (38 mmol/mol) in the second and third trimesters,
respectively.
The proportion of women, who reached the therapeutic
goal of HbA1c< 6.1 % (43 mmol/mol) increased sig-
nificantly from 36.5 % (137 women) in the 1st trimester to
67.2 % (252) and 71.5 % (268 women) in the 2nd and 3rd
trimester, respectively. The distribution of HbA1c in the 3rd
trimester is shown in Fig. 2a. The trend of improving gly-
cemic control was paralleled, to a lesser degree, by changes
in mean daily glucose level indices from SMBG records in
the 1st, 2nd, and 3rd trimester: median 5.9, 5.7, and 5.7
mmol/l, respectively, and by mean fasting glucose in
SMBG records: 5.6, 5.2 and 5.1 mmol/l, respectively.
The median weight gain of the women during pregnancy
was 15 kg.
By design we analyzed term pregnancies; the median
duration of gestation was 39 weeks. Most (66.9 %) preg-
nancies ended with cesarean delivery. The median birth
weight was 3520 g. There were 84 (22.4 %) cases of mac-
rosomia (>4000 g), a large proportion despite excellent
glycemic control, especially in the 2nd and 3rd trimesters.
However, more severe macrosomia was infrequent: there
were 22 newborns (5.9 %) weighting >4500 g and only one
with birth weight >5000 g. In comparison, among 70 cases
of preterm deliveries (20th to 36th week, excluded from the
further analysis) the median birth weight was 2900 g and
there were only 5 cases of macrosomia.
In Table 1 we present comparison between woman–
offspring pairs with and without macrosomia. Mothers of
newborns with macrosomia were slightly younger (median
27 vs. 28 years, p= 0.026) and had longer (p= 0.029)
duration of pregnancy, but did not differ from the rest in
diabetes duration or BMI. Diabetic retinopathy at baseline
had lower prevalence in mothers of macrosomic newborns
(16.6 vs. 28.2 %). There were no differences in diabetes
care: rates of pregnancy planning and analog insulin use
were similar. Mothers of macrosomic newborns (with bor-
derline significance: p= 0.059) were treated more fre-
quently with personal insulin pumps (67.9 vs. 56.4 %). The
most important difference between the macrosomia and
non-macrosomia groups was observed for HbA1c, espe-
cially in the 2nd and 3rd trimesters: 6.0 % (42 mmol/mol)
vs. 5.6 % (38 mmol/mol), p< 0.001 and 6.0 % (42 mmol/
mol) vs. 5.5 % (37 mmol/mol ), p< 0.001, respectively.
Similarly, we observed differences in the 2nd and 3rd tri-
mester (but not the 1st trimester) in mean self-monitored
glucose: 6.0 vs. 5.6 mmol/l (p< 0.001) and 5.9 vs. 5.7
mmol/l (p= 0.001), respectively. Similar differences
were observed for mean postprandial glucose in self-
monitoring, which was highly correlated with mean glu-
cose. No significant differences were observed for mean
glucose amplitude. There was also a significant difference
across all three trimesters between mean fasting self-
monitored glucose. In the 1st trimester it was 6.1 vs. 5.5
mmol/l (p= 0.012), in the 2nd it was 5.7 vs. 5.1 mmol/l (p
< 0.001), and in the 3rd trimester it was 5.4 vs. 5.0 mmol/l
(p< 0.001).
In order to define a set of predictors that independently
contribute to the risk of macrosomia in our cohort we used a
logistic regression model. The resulting set of variables is
shown in Table 2. Gestational age, within the examined
range of 37 to 45 weeks, was strongly associated with birth
weight. One additional week of pregnancy increased the
odds of macrosomia 1.3-fold (p= 0.010). Maternal age (but
not T1DM duration) was associated with lower risk of
macrosomia (odds ratio 0.72 per 5 years increase, p=
0.027). The mother’s baseline (first visit) weight (but not
BMI) was associated with a 1.13-fold increase in odds of
macrosomia (per 5 kg increase), with borderline sig-
nificance (p= 0.054), and this variable was retained in the
final model for its possible confounding properties. The
strongest predictor of birth weight was HbA1c recorded in
the 3rd trimester. Its 1 percentage point increase was asso-
ciated with a 1.68-fold increase in odds of macrosomia (p=
0.001). Independently from HbA1c, the level of mean fast-
ing glucose (measured with personal glucose meter) in the
3rd trimester was associated with a 1.38-fold increase in
odds of macrosomia (per 1 mmol/l increase, p= 0.005).
There was no statistically independent association of mean
blood glucose, mean glucose amplitude or mean post-
prandial glucose from SMBG records and risk of macro-
somia. No marker of glycemia from the 1st or 2nd trimester
had significant effect in the presence of the 3rd trimester
markers.
We also evaluated the predictors listed in Table 2 for
their association with birth weight. The results are con-
sistent with the findings from the logistic models. Briefly, in
the model adjusted for maternal age, gestational age and the
mother’s baseline weight, an increase of HbA1c by 1 per-
centage point was associated with a 136 g higher birth
weight (p< 0.001), and in addition, a 1 mmol/l increase in
mean fasting glucose (SMBG) was associated with a
100 g increase in birth weight (p< 0.001), independently
from HbA1c.
As a sensitivity analysis, we restricted our study group to
women whose HbA1c was <6.5 % (48 mmol/mol) in all
three trimesters. There were 184 such women, and the risk
of macrosomia in this subgroup was 16.3 %. Third trimester
HbA1c remained a significant predictor of macrosomia
(odds ratio 2.87, 95 % CI: 1.17, 7.03, p= 0.022) when
adjusted for maternal age, gestational age and the mother’s
baseline weight. It remained significantly associated with
birth weight (247 g increase per 1 % HbA1c increase, 95 %
CI: 95, 399; p= 0.002). In 124 women with HbA1c
< 6.1 % (43 mmol/mol) there were too few cases of mac-
rosomia (n= 17) to fit a multiple logistic model, but birth
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weight remained dependent from 3rd trimester HbA1c (259
g increase per 1 % HbA1c increase, 95 % CI: 55, 464; p=
0.013).
To further dissect the relationship between the birth
weight and HbA1c in the 3rd trimester, for illustrative pur-
pose, we estimated macrosomia risk in six arbitrary strata of
HbA1c, as shown in Fig. 2b. Although there was an apparent
increase in macrosomia risk in women with HbA1c >5.6 %
(38 mmol/mol), there was no statistically significant differ-
ence in association between macrosomia and HbA1c below
and above this threshold (p= 0.15). To formally determine
the shape of the relationship between HbA1c in the 3rd
trimester and macrosomia and establish a possible target
value of this marker we estimated the risk of this compli-
cation in 15 strata containing 25 women each, ranked by
HbA1c. We plotted the risks against mean HbA1c level in
each stratum (black dots in Fig. 2c) and fitted a Bayesian
penalized splines model to this scatter. It provided a con-
tinuous, nonlinear functional description of the relationship
between HbA1c and macrosomia risk with 95 % Bayesian
credible interval (black line and gray area, respectively in
Fig. 2c). Inspection of this relationship reveals that it is
linear in the HbA1c range from 4.5–7.0 % (26 to 53 mmol/
mol). In this HbA1c range, the Bayesian estimate of mac-
rosomia risk increase per 1 % increase in HbA1c was 12.7
percentage points. The risk of macrosomia predicted from
our data (Fig. 2c) for the 3rd trimester HbA1c 6.0 % (42
mmol/mol) was approximately 25 %. The risk was 10 % for
HbA1c level < 5.0 % (31 mmol/mol).
Discussion
This large observational one-center study has demonstrated
high (above 20 %) prevalence of macrosomia in T1DM-
complicated pregnancies. This phenomenon occurred in
spite of achieving the HbA1c goal of <6.1 % in the 2nd and
3rd trimester by the majority of women.
A quarter century ago, the St Vincent’s Declaration
established, among many others, the goal of improving
outcomes of pregnancies complicated by diabetes to make
them comparable with those observed in non-diabetic
women [22]. In spite of this, as proven in many clinical
observations, macrosomia (defined either as birth weight
above 4000 g or above the 90th percentile) is still very
common in T1DM pregnancies with prevalence of 20–50 %
[5, 8, 23]. Moreover, there has been very little evidence for
the reduction of this most common neonatal outcome of
T1DM-complicated pregnancy. There were reports from
several European countries showing no significant decrease
between surveys performed at different time points over the
last two decades [24–26]. A rare example of an improve-
ment was reported from Ireland, where the Irish Atlantic
Diabetes in Pregnancy (ATLANTIC DIP) group repre-
senting five antenatal centers coordinated specialized care
for women with diabetes before, during, and after
Fig. 2 Third trimester HbA1c and risk of macrosomia. a Distribution
of 3rd trimester HbA1c. Numbers over the bars indicate number of
women. b Risk of macrosomia in strata of 3rd trimester HbA1c. c
Bayesian thin plate regression model illustrating relationship between
the risk of macrosomia and 3rd trimester HbA1c. Dots indicate the
mean HbA1c and observed macrosomia risk in 15 strata containing 25
women each, black line indicates functional relationship between
HbA1c and macrosomia estimated from the observed data and gray
area is 95 % credible interval around the fitted line
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pregnancy [27]. This group reported a 30% drop from the
initial number of neonates born with macrosomia in women
with T1DM [28]. However, their initial HbA1c level was
substantially higher than in our cohort.
Our finding not only confirms but also broadens and
deepens the conclusions of a study [23] performed in the
population of Northern England (Northern Diabetes in
Pregnancy Survey, NORDIP), where the risk of large for
gestational age (LGA) birth weight increased steeply and
monotonically with HbA1c in the range of 5.5–7.0 %
(37–53mmol/mol). In our study group the median HbA1c
levels in the 2nd and 3rd trimester were 1% lower than it was
recorded in the NORDIP study. Thus, we can extend this
observation towards the lower tail of HbA1c distribution. To
avoid possible impact of arbitrary stratification of HbA1c
distribution and random variation, we used a penalized thin-
plate spline model to obtain a flexible functional repre-
sentation of the relationship between the 3rd trimester HbA1c
and macrosomia. Such function can adapt to possible non-
linear relationships, thresholds and plateaus in analyzed data.
We were unable to identify any risk threshold in HbA1c
distribution. There was a linear relationship between the 3rd
trimester HbA1c and the risk of macrosomia, starting from
values of this marker as low as 4.5 % (26mmol/mol). In our
patients the risk of macrosomia was elevated (more than
10%) for HbA1c >5.0% (31 mmol/mol). Interestingly, as in
the NORDIP study, the risk levelled for HbA1c values
>7.0% (53mmol/mol). The risk levels, however, cannot be
compared directly between that study and ours, because we
used macrosomia, rather than percentile chart-based LGA
and SGA (small for gestational age) births.
In a recently published analysis of the relationship
between pregnancy complications and HbA1c in the Dia-
betes and Pre-eclampsia Intervention Trial (DAPIT) popu-
lation the risks of LGA births in strata of 2nd and 3rd
trimester HbA1c were strikingly similar to the ones observed
in the NORDIP study [29]. There was a similar linear
increase of risk followed by a plateau for HbA1c values
>7.0 % (53 mmol/mol). To the best of our knowledge
NORDIP and DAPIT are the only cohorts in which linearity
of the association between LGA and HbA1c in pregesta-
tional diabetes has been formally explored. The unique
value of our study is that it includes a large number (184) of
women with HbA1c during all pregnancy below the current
widely used therapeutic target of 6.5 %. Our results strongly
suggest that macrosomia risk remains glucose-dependent
for HbA1c levels that are significantly lower. Our finding
can be also corroborated by the results of the HAPO study,
which has shown that macrosomia risk can be increased in
women with OGTT glucose values previously perceived as
normal.
The strongest and the most consistent predictor of mac-
rosomia is 3rd trimester HbA1c. In the SMBG profile
association independent from HbA1c was observed only for
mean fasting glucose. Neither mean glucose amplitude nor
postprandial SMBG glucose were associated with macro-
somia, and mean glucose was a much weaker predictor than
HbA1c. This likely reflects deficiency of glucometer mea-
surements in capturing all the variability of glucose levels.
Another possible—although probably less likely—expla-
nation could be the self-reporting nature of analyzed mea-
surements and preferential inclusion of in-target glucose
values by the patients.
The main finding of our study prompts urgent need for
further research into effective means of glucose monitoring
in pregnancy and contradicts the recent shift of target HbA1c
in pregnancy from <6.0 % (42 mmol/mol) to <6.5 % (47
mmol/mol) by NICE and ADA [16, 17]. Despite improve-
ments in diabetes management, macrosomia rates in T1DM
are consistently reported as at least two-fold higher than in
the general population. Attaining currently recommended
HbA1c level does not prevent LGA births and, as a ther-
apeutic target, it is misleading. HbA1c values >4.5 % (26
mmol/mol) remain associated with macrosomia risk, how-
ever, decreasing HbA1c to <6.0 % (42 mmol/mol), values
comparable with observed in the non-diabetic general
population [30] is not feasible in clinical practice. There is
an urgent need to improve the standards of glucose
Table 2 Predictors of
macrosomia in multiple logistic
model analysis and their
association with birth weight in
multiple regression model
analysis
Predictor Association with risk of
macrosomia (logistic model)
Association with birth
weight (linear regression
model)
Odds ratio (95 % CI) P-value Estimate (95 % CI) P-value
Duration of pregnancy (increase by 1 week) 1.27 (1.06, 1.52) 0.010 90 (53, 127) <0.001
Mother’s age (increase by 5 years) 0.72 (0.53, 0.96) 0.027 −78 (−136, −21) 0.008
Mother’s baseline weight (increase by 5 kg) 1.13 (1.00, 1.27) 0.054 30 (4, 56) 0.022
3rd trimester HbA1c (increase by 1 %) 1.68 (1.22, 2.32) 0.001 136 (69, 204) <0.001
3rd trimester mean fasting glucose
(increase by 1 mmol/l)
1.38 (1.10, 1.72) 0.005 100 (54, 147) <0.001
In linear regression effect estimates indicate change of predicted birth weight in grams
CI confidence interval
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monitoring during pregnancy, possibly with wider use of
continuous glucose monitoring. Alternative markers of
hyperglycemia, such as 1,5-anhydroglucitol, which,
according to our earlier finding [31], was a better marker of
maternal glycemic control and predictor of neonatal birth
weight than HbA1c in pregnancies complicated by T1DM,
may possibly find wider application.
This study has several potential shortcomings. It is just
observational research, meaning it is prone to some typical
biases, for example some missing data or unprecise self-
reported glucose measurements. Such biases could possibly
alter the study results, for example by underestimating the
association between the mean glucose amplitude and the
risk of macrosomia. We believe that our study is repre-
sentative for the T1DM population of the Lesser Poland
region, however, we could not exclude that some women
remained under medical care elsewhere and did not parti-
cipate in this study. This is, however, unlikely as medical
care of pregnant T1DM women in Poland is centralized and
it is strongly recommended to refer the patients during
pregnancy planning or at the latest in early pregnancy to
tertiary reference centers like the Department of Metabolic
Diseases in Krakow. Additionally, two limitations related to
laboratory diagnostics should be acknowledged. First, there
were different types of glucose meters used by the patients
from our study over the period of 15 years. Nevertheless,
these were devices from leading global manufacturers, all of
them meeting European accuracy standards. We also did not
control factors potentially affecting the HbA1c level during
complicated pregnancy, such as iron or folic acid deficiency
anemia. While we cannot entirely exclude the influence of
these factors on the study results, this seems to be unlikely.
There are two more important issues that should be
discussed. We chose to use as the outcome macrosomia
defined as birth weight above 4000 g rather than LGA (large
for gestational age) weight. This was related to several
factors. First, we are lacking methodologically correct per-
centile charts from the Polish population for the study
period. Second, there are scientific arguments for such a
choice, since the 4 kg cut-off is a clinically important
indicator of potential complications [8, 23, 26]. Addition-
ally, possible injuries in the newborn or to the birth canal
depend more on the absolute rather than relative size of a
fetus. Moreover, although LGA is widely used in many
countries, its definition relies on the quality and accuracy of
percentile charts, which may differ between particular
regions or time periods. A 4 kg cutoff is easy to compare
between different studies. Finally, we study only term
pregnancies and, additionally, adjust the risk of macrosomia
in the regression models to gestational age. The second
issue is related to the fact that both maternal weight and
BMI were used as candidate independent variables. We
assumed that birth weight may depend not only on mother’s
body fat, but possibly also on her overall body size. Our
analysis showed that maternal pregestational weight, unlike
BMI, was indeed associated with birth weight.
In summary, despite an in-target HbA1c level in most
women, the risk of macrosomia remains high in pregesta-
tional T1DM, and it remains a glucose-dependent compli-
cation. Our study suggests inadequacy of HbA1c and self-
monitoring, as they apparently miss significant episodes of
hyperglycemia.
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